Literature DB >> 1324310

Opioid receptors and their pharmacological profiles.

R A Lutz1, H P Pfister.   

Abstract

Opioid receptors can be divided into three major classes, which are called mu, delta and kappa-receptors. The molecular basis of the receptors is discussed and a hypothesis of the binding of bivalent ligands to the receptor is presented. Furthermore the mechanism of action, the distribution and the probable function of these classes is overviewed. Increasing evidence is accumulating that the classical binding model cannot explain completely the interaction of opioids with their receptors. In addition to the mu-receptors, high affinity mu 1 binding sites have been demonstrated. Similarly, the delta receptors may be divided in delta 1 and delta 2. The significance of these subclasses is not yet fully understood. The high affinity mu 1-binding sites, however, represent probably an activated receptor complex, e.g. the complex between the receptor and the guanine-nucleotide-binding protein.

Mesh:

Substances:

Year:  1992        PMID: 1324310     DOI: 10.3109/10799899209074796

Source DB:  PubMed          Journal:  J Recept Res        ISSN: 0197-5110


  4 in total

1.  Cloning and functional comparison of kappa and delta opioid receptors from mouse brain.

Authors:  K Yasuda; K Raynor; H Kong; C D Breder; J Takeda; T Reisine; G I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

2.  Cloning and pharmacological characterization of a rat kappa opioid receptor.

Authors:  F Meng; G X Xie; R C Thompson; A Mansour; A Goldstein; S J Watson; H Akil
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

Review 3.  Endogenous opioid system: a promising target for future smoking cessation medications.

Authors:  Haval Norman; Manoranjan S D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2017-03-11       Impact factor: 4.530

4.  Agonist-selective endocytosis of mu opioid receptor by neurons in vivo.

Authors:  C Sternini; M Spann; B Anton; D E Keith; N W Bunnett; M von Zastrow; C Evans; N C Brecha
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.